(Q39839596)

15 September 2017

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma (English)

1 reference

15 September 2017

multiple drug resistance

1 reference

1 reference

D Gutman

1

1 reference

15 September 2017

A A Morales

series ordinal

2

1 reference

15 September 2017

L H Boise

series ordinal

3

1 reference

15 September 2017

language of work or name

1 reference

11 June 2009

1 reference

15 September 2017

1 reference

15 September 2017

23

1 reference

15 September 2017

11

1 reference

15 September 2017

2181-2183

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2009.123

15 September 2017

0 references

cites work

Mechanisms of proteasome inhibitor action and resistance in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

Treatment of multiple myeloma: an emphasis on new developments

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

The proteasome: a novel target for cancer chemotherapy

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Gr

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2783738

20 August 2018

Identifiers

DOI

10.1038/LEU.2009.123

1 reference

15 September 2017

1 reference

15 September 2017

PubMed publication ID

19516276

1 reference